Kane Biotech
Kane Biotech is a Winnipeg-based biotechnology company commercializing FDA 510(k)-cleared revyve wound care products that use its proprietary coactiv+® platform and DispersinB® enzyme to disrupt biofilms in chronic wounds, burns, and surgical sites, primarily serving U.S. and Canadian healthcare providers through distributor and federal procurement channels.
- Company typePublic
- Founded2005
- HeadquartersWinnipeg, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kane Biotech does
Kane Biotech Inc. is a Canadian biotechnology company headquartered in Winnipeg, Manitoba, that develops and commercializes technologies to prevent and disperse microbial biofilms in human wound care. The company's commercial portfolio centers on the revyve® product line, which combines a proprietary coactiv+® antimicrobial platform with thermo-reversible gel chemistry that transitions from liquid to gel at body temperature for easy application, wound adherence, and atraumatic removal. The revyve portfolio comprises three FDA 510(k)-cleared products (Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser) and two Health Canada approvals, targeting chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers), burn wounds, and surgical sites. The company also develops the DispersinB® enzyme for biofilm disruption and acquired FB Dermatology's FLETECH tissue regeneration technology in January 2025.
The business model is a regulated medical device sales operation in early commercialization, generating revenue through one-time product sales of FDA-cleared wound care products via a multi-channel distribution model. As of Q1 2026, Kane Biotech had signed non-exclusive distribution and sales agent agreements with Marathon Medical Corporation (federal procurement for VA, DOD, IHS), Patient Care Medical, Life Biologics, Medstream Healthcare Solutions, and Best Buy Medical Canada, while building a contract sales team across the U.S. Pricing is not publicly disclosed, but products are positioned within U.S. reimbursement frameworks. Non-dilutive revenue includes R&D grants from the U.S. Department of Defense ($425,000) and NRC IRAP ($200,000).
In 2025, Kane Biotech underwent significant restructuring, winding down its STEM Animal Health contract manufacturing subsidiary to focus exclusively on revyve-related commercial opportunities. The company is publicly listed on the TSX Venture Exchange (KNE) and US OTC (KNBIF), has 11-50 employees, and is led by interim CEO Dr. Robert Huizinga with Board Chair Philip Renaud holding approximately 27.75% ownership (up to 31.70% on convertible exercise). FY2025 revenue was $427,869 USD with Q1 2026 revenue of $43,218 USD, reflecting the strategic exit from animal health operations. The company has raised approximately $5.3 million through 2024-2026, primarily via insider-led private placements.
Kane Biotech firmographics
Firmographics- Name
- Kane Biotech
- Legal name
- Kane Biotech Inc.
- Website
- https://kanebiotech.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kane Biotech is a Winnipeg-based biotechnology company commercializing FDA 510(k)-cleared revyve wound care products that use its proprietary coactiv+® platform and DispersinB® enzyme to disrupt biofilms in chronic wounds, burns, and surgical sites, primarily serving U.S. and Canadian healthcare providers through distributor and federal procurement channels.
- Ownership category
- akta.pro rank
Kane Biotech industry classification
Industry- Product category
- Advanced Wound Care Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (33911)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Kane Biotech is headquartered
LocationHeadquarters
- HQ city
- Winnipeg
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Kane Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales - revyve Wound Care Portfolio: Revenue generated from the sale of FDA 510(k) cleared and Health Canada approved wound care products including revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The company is in early commercialization phase with multiple distribution partnerships.
- R&D Funding and Government Grants: Non-dilutive funding received from government agencies including NRC IRAP ($200,000 for product expansion) and U.S. Department of Defense ($425,000 for DispersinB Hydrogel clinical development)
Go-to-market motion2 records
Distribution channels6 records
Marketing channels5 records
Kane Biotech product offering
Product offeringCore offering
Kane Biotech develops and commercializes FDA 510(k)-cleared and Health Canada-approved antimicrobial wound care products under the revyve® brand, built on its proprietary coactiv+® platform and DispersinB® biofilm-disrupting enzyme. The portfolio includes revyve Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, with additional products in development for surgical, acne, and tissue regeneration applications. The company sells primarily through medical distributors and federal procurement channels to healthcare providers treating chronic and burn wounds.
Product overview
Kane Biotech is a biotechnology company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. The company's core product portfolio centers on the revyve product line, which includes three FDA 510(k) cleared products: revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The revyve products utilize Kane's proprietary coactiv+ technology platform combined with thermo-reversible gel formulations that provide antimicrobial activity while maintaining a moist wound healing environment. The company is also developing additional wound care and surgical products including coactiv+ Antimicrobial Surgical Hydrogel and DispersinB Hydrogel. In late 2024, Kane announced the acquisition of FB Dermatology, acquiring the patented FLETECH technology for tissue regeneration and dermatology applications.
Differentiator
Problem solved
Functional benefit
Brands
- revyve™ / revyve®: Wound care product line including Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser. FDA 510(k) cleared and Health Canada approved products for treating chronic wounds, burns, and various dermal lesions.
- coactiv+™ / coactiv+®
- DispersinB®
- FLETECH
Products and services
- revyve Antimicrobial Wound Gel A thermo-reversible antimicrobial wound gel combining Kane's patented coactiv+ technology, providing a moist wound healing environment with easy application, firm adherence, and easy rinse-off. FDA 510(k) cleared and Health Canada approved for wound care.
- revyve Antimicrobial Wound Gel Spray A novel non-aerosol gel spray providing zero-contact antimicrobial treatment for traumatic, large surface, and hard-to-reach wounds. Thick gel adheres strongly and is designed for painless delivery and removal. FDA 510(k) cleared and Health Canada approved.
- revyve Antimicrobial Skin and Wound Cleanser FDA 510(k)-cleared wound cleanser for mechanical cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from acute and chronic dermal lesions including pressure ulcers, diabetic foot ulcers, burns, and surgical wounds.
Companies that use Kane Biotech
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Kane Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Kane Biotech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered supporting, core and major.
- University of ManitobasupportingCollaborative research partnership for Frontiers in Antibiotics publication on revyve's effectiveness against antibiotic-tolerant biofilms. Researchers contributed to study demonstrating gel's efficacy in in vitro and ex vivo models.
- Marathon Medical CorporationcoreMarathon Medical Corporation, a federally verified Service-Disabled Veteran-Owned Small Business (SDVOSB), signed as distribution partner to provide access to U.S. Veterans Affairs, Department of Defense, and Indian Health Services markets through established federal procurement contracts. The partnership significantly expands Kane's ability to penetrate U.S. government healthcare systems.
- University of Miami Miller School of MedicinesupportingCo-authorship on International Wound Journal publication demonstrating revyve's efficacy and safety. Researchers from Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery contributed to peer-reviewed validation of thermo-reversible wound gel technology.
- Patient Care MedicalcoreNon-exclusive distribution/sales agreement signed for revyve Antimicrobial Wound Gel product line. Patient Care Medical distributes within Louisiana, Mississippi, and Gulf Coast region specializing in in-hospital and mobile wound care facilities. Initial shipments expected in near term.
- Life BiologicscoreNon-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line. Life Biologics distributes nationally in advanced wound care market, expanding Kane's presence across targeted U.S. sales channels and geographic markets.
- Medstream Healthcare SolutionscoreNon-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line in the United States. Medstream Healthcare Solutions is based in Dorval, Florida and supports Kane's U.S. commercialization restart.
- Best Buy Medical CanadacoreCanadian distribution partner converted to non-exclusive arrangement for revyve Antimicrobial Wound Gel products, supporting broader national penetration with targeted sales and sampling initiatives.
- FB DermatologymajorProposed acquisition of FB Dermatology, an Italian biotech company with operations in Italy, Australia, and New Zealand. Deal valued at $2.5 million including cash, shares, and warrants. Expected to leverage FB Dermatology's patented FLETECH technology for tissue regeneration and dermatology solutions to enhance Kane's market presence and product commercialization.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Kane Biotech competitors and assessment
Company assessmentDirect peers
- Organogenesis: U.S. regenerative medicine company specializing in skin substitutes and active wound care (Apligraf, Dermagraft, PuraPly). Comparable as a direct competitor in advanced/regenerative wound care with overlapping indications (diabetic foot ulcers, venous leg ulcers).
- Urgo Medical: French specialty wound care company with a portfolio of antimicrobial dressings (UrgoClean, UrgoStart) targeting chronic wounds including diabetic foot ulcers. Direct peer in advanced wound care with overlapping indications and similar biofilm-focused product positioning.
- Coloplast: Danish medical device company with a major wound and skin care division including antimicrobial dressings and biofilm-targeting products (e.g., Biatain). Direct peer in advanced wound care with strong U.S. distribution and a focus on chronic wounds similar to Kane's target segments.
- MiMedx: U.S. company commercializing placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Direct peer in advanced wound care with a focus on chronic, non-healing wounds similar to Kane's revyve product line.
- ConvaTec: Specialty medical device company focused on advanced wound care, ostomy, and continence care. Direct competitor in antimicrobial wound dressings and gels; Kane's VP Patti Burke-Martin previously held senior roles at ConvaTec, reflecting the overlapping customer base (podiatrists, wound care nurses, hospitals).
Broad incumbents
- Smith & Nephew: Global medical device company with the Advanced Wound Management division; competes directly in wound gels, antimicrobial dressings, and skin substitutes. Comparable as a broad incumbent offering overlapping chronic wound care solutions through established hospital and distribution channels.
- Integra LifeSciences: Medical device company with a strong regenerative tissue and wound care portfolio (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel). Broad incumbent offering overlapping solutions to hospitals and burn centers — relevant for Kane's burn care segment with revyve Gel Spray.
- Mölnlycke Health Care: Swedish wound care and surgical solutions company with Mepilex, Mepitel, and other advanced wound dressings including antimicrobial variants. Comparable broad incumbent in the same hospital and outpatient wound care channels Kane targets with revyve.
- 3M Health Care (Solventum): Spun off from 3M, Solventum's Health Care segment includes a large advanced wound care portfolio (Tegaderm, Cavilon). Comparable broad incumbent with significant U.S. distribution, formulary access, and clinician relationships in the same channels Kane is building.
Emerging players
- Carnegie Pharmaceuticals: Smaller specialty wound care company with hydrogel and barrier products; comparable as a niche emerging player in advanced wound care with overlapping product formats (hydrogel-based) and similar target customer segments (podiatry, wound clinics).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Kane Biotech social profiles
Digital presenceKane Biotech compliance and trust
Trust signalCompliance3 records
Kane Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kane Biotech leadership team
Management profileNumber of profiles
Profiles10 records
Kane Biotech subsidiaries and ownership
Company hierarchySubsidiaries2 records
Kane Biotech funding detail
Funding detailFunding overview
Funding rounds29 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kane Biotech M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kane Biotech
What does Kane Biotech do?
Kane Biotech develops and commercializes FDA 510(k)-cleared and Health Canada-approved antimicrobial wound care products under the revyve® brand, built on its proprietary coactiv+® platform and DispersinB® biofilm-disrupting enzyme. The portfolio includes revyve Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, with additional products in development for surgical, acne, and tissue regeneration applications. The company sells primarily through medical distributors and federal procurement channels to healthcare providers treating chronic and burn wounds.
Is Kane Biotech a public or private company?
Kane Biotech is a public company. It is classified as public and is currently operating.
When was Kane Biotech founded?
Kane Biotech was founded in 2005. It employs 11 to 50 people.
Where is Kane Biotech based?
Kane Biotech is headquartered in Winnipeg, Canada, in the North America region.
How does Kane Biotech make money?
Two revenue lines are on record. Product Sales - revyve Wound Care Portfolio is the primary driver. The others are R&D Funding and Government Grants.
Who are Kane Biotech's main competitors?
Direct peers on record are Organogenesis, Urgo Medical, Coloplast, MiMedx and ConvaTec. Broad incumbents are Smith & Nephew, Integra LifeSciences, Mölnlycke Health Care and 3M Health Care (Solventum). Carnegie Pharmaceuticals is listed as an emerging player.
Does Kane Biotech have an API?
No public API is recorded for Kane Biotech.
What industry is Kane Biotech in?
Kane Biotech's product category is Advanced Wound Care Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 3391 and its SIC code is 3841.